

Constantine Mitsiades

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10428197/publications.pdf>

Version: 2024-02-01

74
papers

10,899
citations

53939

47
h-index

104191

69
g-index

77
all docs

77
docs citations

77
times ranked

10764
citing authors

#	ARTICLE	IF	CITATIONS
1	A biphenyl inhibitor of eIF4E targeting an internal binding site enables the design of cell-permeable PROTAC-degraders. <i>European Journal of Medicinal Chemistry</i> , 2021, 219, 113435.	2.6	15
2	The power of proteasome inhibition in multiple myeloma. <i>Expert Review of Proteomics</i> , 2018, 15, 1033-1052.	1.3	33
3	Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. <i>Leukemia</i> , 2015, 29, 27-37.	3.3	51
4	Upregulation of IGF1R by Mutant <i>RAS</i> in Leukemia and Potentiation of <i>RAS</i> Signaling Inhibitors by Small-Molecule Inhibition of IGF1R. <i>Clinical Cancer Research</i> , 2014, 20, 5483-5495.	3.2	16
5	Pomalidomide for the treatment of relapsed and refractory multiple myeloma. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 1089-1108.	0.5	1
6	Novel Agents in Multiple Myeloma. , 2013, , 215-228.		0
7	New Proteasome Inhibitors in Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 258-266.	1.2	89
8	Lenalidomide for the treatment of relapsed and refractory multiple myeloma. <i>Cancer Management and Research</i> , 2012, 4, 253.	0.9	28
9	A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. <i>Proteomics</i> , 2011, 11, 1391-1402.	1.3	33
10	A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. <i>Blood</i> , 2010, 115, 3772-3775.	0.6	56
11	Complications of Multiple Myeloma Therapy, Part 1: Risk Reduction and Management of Peripheral Neuropathy and Asthenia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, S-4-S-12.	2.3	33
12	Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. <i>Core Evidence</i> , 2010, 4, 215.	4.7	18
13	Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy. <i>Journal of Clinical Oncology</i> , 2009, 27, 3518-3525.	0.8	241
14	Bortezomib induces canonical nuclear factor- κ B activation in multiple myeloma cells. <i>Blood</i> , 2009, 114, 1046-1052.	0.6	329
15	Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target. <i>Cancer Cell</i> , 2009, 16, 309-323.	7.7	242
16	Novel Combination Therapies for the Treatment of Relapsed/Refractory Multiple Myeloma: Current Phase I/II Combinations. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S40-S42.	1.4	0
17	Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. <i>Blood</i> , 2009, 114, 371-379.	0.6	364
18	Bortezomib in the front-line treatment of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1053-1072.	1.1	79

#	ARTICLE	IF	CITATIONS
19	Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. <i>Leukemia and Lymphoma</i> , 2008, 49, 502-507.	0.6	185
20	Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 374-375.	4.3	2
21	TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application. <i>Blood</i> , 2008, 112, 2737-2737.	0.6	0
22	Targeting the β -catenin/TCF transcriptional complex in the treatment of multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 7516-7521.	3.3	197
23	Emerging drugs in multiple myeloma. <i>Expert Opinion on Emerging Drugs</i> , 2007, 12, 155-163.	1.0	11
24	Potential of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1951-1961.	1.9	78
25	New Drugs for Myeloma. <i>Oncologist</i> , 2007, 12, 664-689.	1.9	145
26	The Treatment of Relapsed and Refractory Multiple Myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 317-323.	0.9	53
27	Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). <i>Blood</i> , 2007, 109, 1220-1227.	0.6	144
28	Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. <i>Blood</i> , 2007, 109, 3177-3188.	0.6	379
29	The Emerging Role of Novel Therapies for the Treatment of Relapsed Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, 149-162.	2.3	59
30	Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. <i>Nature Reviews Cancer</i> , 2007, 7, 585-598.	12.8	817
31	Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. <i>British Journal of Haematology</i> , 2007, 138, 783-791.	1.2	102
32	Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy. <i>Annual Review of Medicine</i> , 2006, 57, 33-47.	5.0	317
33	Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. <i>Blood</i> , 2006, 107, 4053-4062.	0.6	398
34	Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. <i>Current Opinion in Oncology</i> , 2006, 18, 598-608.	1.1	32
35	Proteasome Inhibition as a New Therapeutic Principle in Hematological Malignancies. <i>Current Drug Targets</i> , 2006, 7, 1341-1347.	1.0	40
36	Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib*. <i>British Journal of Haematology</i> , 2006, 134, 145-156.	1.2	94

#	ARTICLE	IF	CITATIONS
37	MLN120B, a Novel I κ B Kinase \hat{I}^2 Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo. <i>Clinical Cancer Research</i> , 2006, 12, 5887-5894.	3.2	130
38	Lenalidomide in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1165-1173.	1.1	50
39	Bortezomib Induces Proliferation of Mesenchymal Progenitor Cells and Promotes Differentiation towards Osteoblastic Lineage.. <i>Blood</i> , 2006, 108, 88-88.	0.6	13
40	Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)- \hat{I}^2 inhibitors. <i>Oncogene</i> , 2005, 24, 3121-3129.	2.6	43
41	A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. <i>Cancer Cell</i> , 2005, 8, 407-419.	7.7	673
42	Proteasome inhibitor therapy in multiple myeloma. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 686-692.	1.9	148
43	Bortezomib: proteasome inhibition as an effective anticancer therapy. <i>Future Oncology</i> , 2005, 1, 161-167.	1.1	33
44	Proteasome Inhibition in the Treatment of Cancer. <i>Cell Cycle</i> , 2005, 4, 289-295.	1.3	92
45	Targeting Bcl-2 as Therapy for Multiple Myeloma.. <i>Blood</i> , 2005, 106, 109-109.	0.6	5
46	Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052.. <i>Blood</i> , 2005, 106, 3378-3378.	0.6	1
47	Proteasome inhibition in the treatment of cancer. <i>Cell Cycle</i> , 2005, 4, 290-6.	1.3	42
48	Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341. <i>Oncogene</i> , 2004, 23, 3597-3602.	2.6	54
49	p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. <i>Oncogene</i> , 2004, 23, 8766-8776.	2.6	127
50	Proteasome inhibition in hematologic malignancies. <i>Annals of Medicine</i> , 2004, 36, 304-314.	1.5	59
51	Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological Activity. <i>Mayo Clinic Proceedings</i> , 2004, 79, 875-882.	1.4	120
52	Identification of genes modulated in multiple myeloma using genetically identical twin samples. <i>Blood</i> , 2004, 103, 1799-1806.	0.6	127
53	Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. <i>Blood</i> , 2004, 103, 1787-1790.	0.6	266
54	The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti- multiple myeloma (MM) activity and overcome bortezomib resistance. <i>Blood</i> , 2004, 103, 3158-3166.	0.6	122

#	ARTICLE	IF	CITATIONS
55	Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. <i>Blood</i> , 2004, 104, 2458-2466.	0.6	79
56	Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. <i>Blood</i> , 2004, 104, 4188-4193.	0.6	177
57	A Novel Orally Available Proteasome Inhibitor NPI-0052 Induces Killing in Multiple Myeloma (MM) Cells Resistant to Conventional and Bortezomib Therapies.. <i>Blood</i> , 2004, 104, 2405-2405.	0.6	3
58	Comprehensive Genome-Wide Profile of Regional Gains and Losses in Multiple Myeloma Using Array-CGH: The 1q21 Amplification and Potential Role of the BCL-9 Gene in Multiple Myeloma Pathogenesis.. <i>Blood</i> , 2004, 104, 785-785.	0.6	4
59	The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development. <i>Current Cancer Drug Targets</i> , 2004, 4, 235-256.	0.8	240
60	Atiprimod (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.. <i>Blood</i> , 2004, 104, 2401-2401.	0.6	0
61	Increased TCF-4 Expression Correlates with Reduced Caspase-3 Induction and Confers Resistance to Bortezomib.. <i>Blood</i> , 2004, 104, 285-285.	0.6	1
62	Targeting Mitochondrial Factor Smac/DIABLO as Therapy for Multiple Myeloma (MM).. <i>Blood</i> , 2004, 104, 764-764.	0.6	0
63	Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. <i>Oncogene</i> , 2003, 22, 8386-8393.	2.6	163
64	Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. <i>Blood</i> , 2003, 102, 4504-4511.	0.6	212
65	JNK-dependent Release of Mitochondrial Protein, Smac, during Apoptosis in Multiple Myeloma (MM) Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 17593-17596.	1.6	180
66	Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. <i>Blood</i> , 2003, 101, 1530-1534.	0.6	533
67	Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. <i>Blood</i> , 2003, 101, 3606-3614.	0.6	67
68	Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. <i>Blood</i> , 2003, 102, 3379-3386.	0.6	147
69	CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF- κ B signaling. <i>Blood</i> , 2003, 101, 2762-2769.	0.6	111
70	Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. <i>Cancer Research</i> , 2003, 63, 5850-8.	0.4	159
71	Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. <i>Cancer Research</i> , 2003, 63, 8428-36.	0.4	54
72	Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. <i>Blood</i> , 2002, 100, 3063-3067.	0.6	759

#	ARTICLE	IF	CITATIONS
73	NF- κ B as a Therapeutic Target in Multiple Myeloma. <i>Journal of Biological Chemistry</i> , 2002, 277, 16639-16647.	1.6	824
74	Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. <i>Blood</i> , 2001, 98, 428-435.	0.6	399